A Phase 1, Open-label, Dose Escalation Study Of Pf-04518600 As A Single Agent And In Combination With Pf-05082566 In Patients With Selected Locally Advanced Or Metastatic Cancers
Phase of Trial: Phase I
Latest Information Update: 14 Sep 2017
At a glance
- Drugs PF 4518600 (Primary) ; Utomilumab
- Indications Head and neck cancer; Liver cancer; Malignant melanoma; Renal cell carcinoma
- Focus Adverse reactions; First in man
- Sponsors Pfizer
- 12 Sep 2017 Results presented at the 42nd European Society for Medical Oncology Congress.
- 11 Sep 2017 Planned End Date changed from 26 Aug 2020 to 1 Aug 2020.
- 11 Sep 2017 Planned primary completion date changed from 31 Dec 2018 to 1 Dec 2018.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History